Nile Pharmaceuticals results, Q3 2025
Net profit, assets, equity and cash flow for Q3 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit57.98 millionEGP · +120.0% vs the same period a year earlier
Shareholders' equity742 millionEGP · +44.1% vs the same period a year earlier
Operating cash flow-73.9 millionEGP · −166.6% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q3 2025 was about 57.98 million EGP, up +120.0% from 26.36 million EGP in Q3 2024.
- Operating cash flow for Q3 2025 was negative at 73.9 million EGP.
Key lines against the same period a year earlier
This periodQ3 2024Change
Net profit57.98 million26.36 million+120.0%
Gross profit-208 million73.29 million−383.6%
Total assets—1.42 billion—
Total liabilities—905 million—
Shareholders' equity742 million515 million+44.1%
Total liabilities and equity1.99 billion1.42 billion+39.8%
Operating cash flow-73.9 million111 million−166.6%
Investing cash flow-101 million-168 million+39.9%
Financing cash flow161 million168 million−4.1%
Net change in cash—111 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy